MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT

MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.

Subsidie
€ 2.863.733
2024

Projectdetails

Introduction

MULTISCOPE introduces a revolutionary photonic technology that represents a significant advancement in the field of optical diagnostics and therapy. Our approach is based on cutting-edge research into pulse propagation within nonlinear complex structures.

Device Development

We are developing an endoscopic device that seamlessly combines optical biopsy and cold atmospheric plasma treatment. This dual-functionality device harnesses the spatiotemporal control of powerful light in multimode fibers, which were previously overlooked due to concerns about excessive light destructuring.

Technological Advancements

We leverage the remarkable progress in the development of the latest optical fibers and in the precise control of light within multimode guides, enabling us to harness the power of plasma, the fourth state of matter.

Focus Areas

Initially, our focus is on gastrointestinal (GI) endoscopy, but our ultimate goal is to extend this technology to all areas of medical diagnostics where there is a pressing need for reliable tools for "optical biopsy" and "instant pathology." These tools are crucial for real-time diagnosis but have not yet reached the level of trustworthiness required for widespread use.

Importance of Endoscopy

Endoscopy is a vital tool for diagnosing and treating GI disorders, offering a safe and effective approach. However, the current standard of care still relies on histopathology for conclusive cancer diagnosis. This leads to significant delays in initiating treatment and incurs high costs.

Project Goals

Our project is set to transform this landscape by bringing to life the long-anticipated concept of real-time, in-vivo optical diagnosis, often referred to as "optical biopsy."

Integration of Technologies

Our groundbreaking approach seamlessly integrates endoscopic capabilities with cold atmospheric plasma therapy, which employs controlled plasma jets to precisely target and eliminate cancer cells by inducing cellular apoptosis.

Conclusion

By combining plasma therapy with optical biopsy, we not only provide real-time diagnosis but also offer immediate therapeutic intervention.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.863.733
Totale projectbegroting€ 2.863.733

Tijdlijn

Startdatum1-12-2024
Einddatum30-11-2027
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZApenvoerder
  • UNIVERSITE DE LIMOGES
  • UNIVERSITA CATTOLICA DEL SACRO CUORE
  • FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
  • Erbe Elektromedizin GmbH
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Land(en)

ItalyFranceGermany

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Hybrid endoscope for esophageal in vivo histology and histochemistry

ESOHISTO aims to revolutionize GI cancer diagnosis through innovative endoscopic technologies that enable real-time 3D imaging of diseased tissues, enhancing early detection and treatment.

€ 3.046.127
EIC Pathfinder

ADAPTIVE OPTICAL METASURFACES FOR REAL-TIME, LABEL-FREE AND NON-DESTRUCTIVE 7D DIGITAL PATHOLOGY

OPTIPATH aims to revolutionize tissue diagnosis by providing real-time, non-destructive 3D imaging using advanced optical technologies and machine learning to enhance accuracy and reduce variability.

€ 3.276.577
EIC Pathfinder

A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.

€ 2.792.500
EIC Pathfinder

On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology

DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.

€ 3.018.312
EIC Pathfinder

Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer

BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.

€ 3.069.321

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

In vivo Immunofluorescence-Optical Coherence Tomography

Develop a high-resolution endoscopic imaging system combining Optical Coherence Tomography and fluorescent antibodies for improved diagnosis and treatment of esophageal cancer and lung disease.

€ 2.500.000
EIC Accelerator

Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery

Thericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024.

€ 2.500.000
ERC Starting...

FunctIonal optoacousticS for imaging Early onsEt of Gut inflammation

This project aims to develop functionalized contrast agents for multispectral optoacoustic tomography to enable non-invasive early detection of gastrointestinal inflammation.

€ 1.453.730
ERC Synergy ...

Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and Therapy

EndoTheranostics aims to revolutionize colorectal cancer screening and treatment through a robotic system that enables painless preparation, real-time polyp detection, and effective removal using advanced imaging and tools.

€ 7.616.426
ERC Proof of...

Method for Integrated All-Optical Biological Analysis at Scale

Developing an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer.

€ 150.000